Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL) - PubMed
5 hours ago
- #immunotherapy
- #liver transplantation
- #hepatocellular carcinoma
- Liver transplantation (LT) efficacy after atezolizumab-bevacizumab (Atezo-Bev) downstaging in intermediate/advanced HCC.
- Prospective phase II study with 16 HCC patients beyond extended transplant criteria.
- Median tumor size: 6.5 cm; 50% had portal vein thrombosis; median AFP 283.
- Downstaging to LT achieved after median 4.7 months of Atezo-Bev treatment.
- Pre-transplant immune-related adverse events: 19%; post-transplant acute rejection: 25%.
- 90-day post-LT morbidity: 62.5%; mortality: 6.3%.
- Explant pathology: 10 complete responses, 6 partial responses.
- Tumor microenvironment showed immune activation/extinguishment linked to treatment duration.
- Post-LT HCC recurrence: 6.2%; 2-year RFS: 90%; overall survival: 94%.
- LT after Atezo-Bev offers competitive outcomes for advanced HCC beyond standard criteria.